This inventor holds 2 USPTO granted patents. Top assignees: Innovent Biologics (Suzhou) Co., Ltd., Beijing Hanmi Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Kaisong Zhou: Innovator in Bispecific Antibody Development
Introduction
Kaisong Zhou is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Kaisong Zhou holds a patent for a formulation comprising an anti-PD-1/HER2 bispecific antibody, along with the method for preparing the same and its use. This patent represents a crucial step in the fight against cancer, as bispecific antibodies have the potential to enhance the efficacy of immunotherapy.
Career Highlights
Throughout his career, Zhou has worked with notable companies in the pharmaceutical industry. He has been associated with Innovent Biologics (Suzhou) Co., Ltd. and Beijing Hanmi Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to hone his skills and contribute to groundbreaking research.
Collaborations
Kaisong Zhou has collaborated with talented individuals in his field, including Yanghan Liu and Yidong Ma. These partnerships have fostered an environment of innovation and creativity, leading to advancements in biopharmaceutical research.
Conclusion
Kaisong Zhou is a distinguished inventor whose work in bispecific antibodies is paving the way for new therapeutic options in cancer treatment. His contributions to the field are invaluable, and his ongoing research promises to make a significant impact on medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile